Who are Vyvanse (lisdexamphetamine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propadrine, Didrex, Tenuate, Aramine, Vialin, mixed salts amphetamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vyvanse-lisdexamphetamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vyvanse (lisdexamphetamine) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vyvanse (lisdexamphetamine) (Vyvanse (lisdexamphetamine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine; amphetamine prodrug. Area: Psychiatry/Neurology.

marketed Sympathomimetic amine; amphetamine prodrug Norepinephrine transporter (NET); dopamine transporter (DAT) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Vyvanse (lisdexamphetamine) (Vyvanse (lisdexamphetamine)) — Seattle Children's Hospital. Lisdexamphetamine is a prodrug that is converted in the body to dexamphetamine, which increases the release and blocks the reuptake of norepinephrine and dopamine in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vyvanse (lisdexamphetamine) TARGET	Vyvanse (lisdexamphetamine)	Seattle Children's Hospital	marketed	Sympathomimetic amine; amphetamine prodrug	Norepinephrine transporter (NET); dopamine transporter (DAT)
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	marketed	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Didrex	BENZPHETAMINE	Pfizer	marketed	Sympathomimetic Amine Anorectic	Alpha-1A adrenergic receptor	1960-01-01
Tenuate	DIETHYLPROPION	ANI Pharmaceuticals	marketed	Sympathomimetic Amine Anorectic	Sodium-dependent dopamine transporter	1959-01-01
Aramine	METARAMINOL		marketed	Indirectly Acting Sympathomimetic Amines	Macrophage migration inhibitory factor	1954-01-01
Vialin	MEPHENTERMINE	Baxter	marketed	Indirectly Acting Sympathomimetic Amines	Alpha-1A adrenergic receptor	1951-01-01
mixed salts amphetamine	mixed salts amphetamine	Rush University Medical Center	marketed	Sympathomimetic amine; CNS stimulant	Dopamine transporter (DAT); Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine; amphetamine prodrug class)

NYU Langone Health · 1 drug in this class
Seattle Children's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vyvanse (lisdexamphetamine) — Competitive Intelligence Brief. https://druglandscape.com/ci/vyvanse-lisdexamphetamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing